- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03601091
EFFECT OF DEXMEDETOMİDİNE AND MİDAZOLAM SEDATİON ON HEART RATE VARİABİLİTY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY
May 7, 2021 updated by: mustafa emre gürcü, Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
RANDOMİZED,DOUBLE-BLİND TRİAL OF EFFECT OF DEXMEDETOMİDİNE AND MİDAZOLAM SEDATİON ON HEART RATE VARİABİLİTY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY
The parasympathetic tone reduction and sympathetic tone enhancement, which are components of the autonomic nervous system (ANS) activity, increase the likelihood of malignant arrhythmias leading to ventricular fibrillation.
Malignant arrhythmias are associated with high mortality and morbidity after coronary artery bypass graft (CABG) surgeries.
Heart rate variability (HRV) is a physiological indicator of the effects of ANS activity on heart rate and is associated with a prognostic value for cardiac mortality.
Dexmedetomidine has been shown to improve myocardial perfusion, reduce arrhythmia incidence, reduce inflammatory response, and reduce mortality in patients with coronary artery disease.
The aim of this study investigate the effects of dexmedetomidine electrophysiologically on cardiac autonomic system by using HRV analysis for the purpose of sedation in patients who were followed up in the intensive care unit after coronary artery bypass graft surgery
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Malignant arrhythmias are associated with high mortality and morbidity after coronary artery bypass graft (CABG) operations.
Heart rate variability (HRV) is a physiological indicator of the effects of activity on heart ANS rate and has prognostic value for cardiac mortality.
Spectral analysis of HRV can provide an assessment of adrenergic and cholinergic system activities during anesthesia.
With the "power spectral" analysis of HRV, important clinical information can be obtained about the effects of anesthesia on the autonomic nervous system and the central nervous system.
Decrease in HRV has a prognostic value for cardiac-induced mortality.
The disease, which is transferred to intensive care unit (ICU) after CABG, is sedated with different medicines until the time of extubation.
One commonly used sedative drug is deksmedetomidine, an α2 receptor agonist.
Alpha 2 (α2) receptor agonist drugs reduce myocardial oxygen consumption and heart rate with sympatholytic properties.
Therefore, deksmedetomidine can be safely and effectively used in patients undergoing cardiac surgery without pro-tachyarrhythmic and / or negative inotropic effects.In this study, it was aimed to investigate electrophysiologic effects of cardiac autonomic system by using HRV analysis in dexmedetomine and midazolam patients who underwent elective CABG and were used for sedation in the postoperative period.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey, 34865
- Mustafa Emre Gurcu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with pre-operative normal sinus rhythm
- Ejection fraction (EF)> 45% on echocardiography (echocardiography) examination
- 25 and 65 years of age will be included.
Exclusion Criteria:
- Atrial fibrillation , atrial flutter, supraventricular tachycardia , AV block, ventricular extrasystole
- Cardiopulmonary bypass have been reported in patients with diabetes mellitus (DM),
- Chronic obstructive pulmonary disease (COPD),
- Previous cerebrovascular event will be excluded from the study.
- Patients receiving high-dose inotropic drug support after surgery (inotropic score of> 10 in the first 24 hours) and
- Patients re-operated for bleeding revision will be removed from the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PR
PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
|
Infusion therapy of the drug
|
Active Comparator: DO
DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
|
Infusion therapy of the drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart rate variability
Time Frame: 24 hours
|
Low and high frequency of heart rate regarding with aritmia incidence
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2018
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
December 31, 2021
Study Registration Dates
First Submitted
June 27, 2018
First Submitted That Met QC Criteria
July 17, 2018
First Posted (Actual)
July 26, 2018
Study Record Updates
Last Update Posted (Actual)
May 10, 2021
Last Update Submitted That Met QC Criteria
May 7, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
- Dexmedetomidine
Other Study ID Numbers
- 2018/3/53
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Effect of Sedation on Heart Rate Variability
-
Charite University, Berlin, GermanyTerminatedInfluence of Espresso on Heart Rate VariabilityGermany
-
Tampa General HospitalWithdrawnEffect of Protocolized Sedation on Days of Mechanical Ventilation in the ICUUnited States
-
University of Southern CaliforniaTerminated
-
National Taiwan University HospitalUnknownHeart Rate VariabilityTaiwan
-
University of Sao PauloUnknownHeart Rate VariabilityBrazil
-
Kaohsiung Medical UniversityCompleted
-
University of California, IrvineNational Institute on Minority Health and Health Disparities (NIMHD); Emory...Recruiting
-
Université du Québec a MontréalCollège d'Études Ostéopathiques de MontrealCompletedHeart Rate VariabilityCanada
-
Imam Abdulrahman Bin Faisal UniversityCompletedHeart Rate VariabilitySaudi Arabia
-
Florida State UniversityCompletedHeart Rate Variability | Appetite | Resting Metabolic RateUnited States
Clinical Trials on Precedex 200 MCG in 2 ML Injection
-
Seoul National University HospitalSMG-SNU Boramae Medical CenterCompleted
-
Universidade Federal do Rio de JaneiroRio de Janeiro State Research Supporting Foundation (FAPERJ)Completed
-
University of Michigan Rogel Cancer CenterWithdrawnProstate CancerUnited States
-
Diskapi Teaching and Research HospitalCompleted
-
Hospital Israelita Albert EinsteinBristol-Myers Squibb; BravaRecruiting
-
AbbottMassachusetts General Hospital; Harvard UniversityTerminatedHypertrophy, Left Ventricular | Chronic Kidney Disease (CKD) Stage 5Italy, United States, Taiwan, Poland, United Kingdom, Greece, Germany, Russian Federation, Spain, Australia, Czech Republic, Puerto Rico, Romania
-
Universiti Kebangsaan Malaysia Medical CentreCompletedOpioid Use, Unspecified | Laparotomy Surgery | Post-Operative AnalgesiaMalaysia
-
Kadmon Corporation, LLCQuotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
EirGenix, Inc.Sacura GmbHCompleted
-
GERCOR - Multidisciplinary Oncology Cooperative...Bristol-Myers SquibbActive, not recruitingMetastatic Cancer ColorectalFrance